Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care
Supportive Care in Cancer · 2026-11 · 34 (11)
DOI: 10.1007/s00520-026-11340-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 19.10.2026. Verfasst von Vanessa Rouach und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky University Medical Center, Tel Aviv, Israel. vanessar@tlvmc.gov.il. Hauptthemen laut MEDLINE: Bone Density, Absorptiometry, Photon, Neoplasms, Osteoporosis. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Cancer treatment–induced bone loss (CTIBL) is well-recognized in hormone-sensitive malignancies such as breast and prostate cancer but is less consistently implemented in patients with other solid tumors and hematologic malignancies. Furthermore, the long-term skeletal effects of newer systemic therapies, including immune checkpoint inhibitors and targeted agents, remain incompletely characterized. Although bone mineral density (BMD) assessment by dual-energy X-ray absorptiometry (DXA) is recommended for patients at increased skeletal risk, real-world utilization patterns remain poorly characterized.
Objectives
To evaluate DXA utilization, timing, BMD results, and associated clinical characteristics following a new cancer diagnosis in a large real-world cohort.
Methods
We conducted a retrospective cohort study using the MDClone platform, including adults with a first cancer diagnosis between January 1, 2015, and December 31, 2024, treated at Assuta Medical Centers in Israel. DXA completion, timing, BMD and T -scores, and prevalence of osteopenia and osteoporosis were analyzed.
Results
Among 21,112 patients with newly diagnosed cancer (77.0% women; mean age 60.2 ± 13.1 years), 7496 (35.5%) underwent DXA at any time following diagnosis. DXA utilization was significantly lower in men than in women (15.0% vs. 41.7%). Early DXA assessment within 6 months of diagnosis was uncommon (1550 patients; 7.3% of the total cohort), and only 14.1% underwent DXA within the first 12 months. Median time from cancer diagnosis to DXA was 14.8 months. DXA utilization varied by cancer type and was highest in breast cancer (42.2%) and prostate cancer (30.0%), with substantially lower utilization among patients with other malignancies. Among patients with complete evaluable measurements, 40.2% had normal BMD, 45.2% had osteopenia, and 14.5% met criteria for osteoporosis.
Conclusions
In our real-world experience within a large private healthcare network, DXA assessment after cancer diagnosis is infrequently performed and often delayed, with marked disparities by sex and cancer type. A substantial burden of low bone mass is already present at the time of evaluation, highlighting missed opportunities for early skeletal risk identification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky University Medical Center, Tel Aviv, Israel. vanessar@tlvmc.gov.il.
- Gray School of Medicine, The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. vanessar@tlvmc.gov.il.
- Assuta Medical Centers, Tel Aviv, Israel. vanessar@tlvmc.gov.il.
- Assuta Medical Centers, Tel Aviv, Israel.
- Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky University Medical Center, Tel Aviv, Israel.
- Gray School of Medicine, The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Zitieren
APA
Rouach, V., Versano, Z., Sasson, M., Greenman, Y., & Makori, A. (2026). Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care. Supportive Care in Cancer, 34(11). https://doi.org/10.1007/s00520-026-11340-3
Vancouver
Rouach V, Versano Z, Sasson M, Greenman Y, Makori A. Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care. Supportive Care in Cancer. 2026;34(11). doi:10.1007/s00520-026-11340-3
BibTeX
@article{Rouach2026,
author = {Rouach, Vanessa and Versano, Ziv and Sasson, Meital and Greenman, Yona and Makori, Arnon},
title = {Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {11},
doi = {10.1007/s00520-026-11340-3}
}
EUVIMED